Feb. 5, 2021 — The world’s first single-dose COVID-19 vaccine, from Johnson & Johnson, has been submitted to the U.S. Meals and Drug Administration for emergency use approval.
Preliminary findings from a big worldwide research recommend the vaccine is not fairly as robust as the 2 present FDA-approved vaccines from Pfizer and Moderna, that are two-dose vaccines, the Related Press reported.
Nonetheless, the J&J vaccine is less complicated to make use of and will ease COVID-19 vaccine shortages.
An FDA advisory panel will evaluate knowledge on the brand new vaccine on Feb. 26. The FDA will then resolve whether or not to approve it.
FDA Vaccine Chief Dr. Peter Marks has cautioned in opposition to making comparisons between vaccines earlier than the entire proof is collected.
“With a lot have to get this pandemic below management, I believe we will not ignore any software within the software chest,” he informed the American Medical Affiliation final week, the AP reported. “We should do our greatest to attempt to guarantee that we discover the populations that profit probably the most from every of those vaccines and deploy them in a really considerate method.”
The J&J vaccine was 66% efficient at stopping average to extreme COVID-19, and 85% protecting in opposition to probably the most critical signs, based on early outcomes of the clinical trial that included 44,000 individuals in the US, Latin America and South Africa, the AP reported.
And beginning 28 days after receiving the vaccine, nobody who obtained it required hospitalization or died.